![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
ACTG 5360 is a combination of sofosbuvir which is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, whereas velpatasvir is an inhibitor of the HCV NS5A protein, both required for viral replication. Currently being studied for chronic hepatitis C treatment.
Lead Product(s): Sofosbuvir,Velpatasvir
Therapeutic Area: Infections and Infectious Diseases Product Name: ACTG 5360
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction. Five of these molecules are already FDA-approved for use in the treatment of other viral infections.
Lead Product(s): Sofosbuvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020